In a report released today, James Terwilliger from Northland Securities maintained a Buy rating on Sensus Healthcare (SRTS), with a price target of $7.75. The company’s shares closed last Monday at $4.80.
According to TipRanks.com, Terwilliger is a 4-star analyst with an average return of 19.6% and a 76.2% success rate. Terwilliger covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Milestone Scientific, and Infusystems Holdings.
Currently, the analyst consensus on Sensus Healthcare is a Strong Buy with an average price target of $6.58.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.09 and a one-year low of $2.32. Currently, Sensus Healthcare has an average volume of 46.41K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
